Zydus Lifesciences Limited: Breast Neoplasms trials

The registry lists 10 Breast Neoplasms studies with Zydus Lifesciences Limited as lead sponsor. 0 are open to participants now and 5 have results posted.

Phase 1 3Phase 2 3Phase 3 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedNCT04172597Phase 2Results posted
• A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedNCT03744715Phase 2Results posted
• SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and CyclophosphamideCompletedNCT02953340Phase 3Results posted
• Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedNCT02659514Phase 2Results posted
• SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)CompletedNCT02643420Phase 3Results posted
• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)CompletedNCT05283837Phase 3
• Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-CancerCompletedNCT04187898Phase 1
• A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedNCT03429101Phase 1
• Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) ChemotherapyCompletedNCT03135951Phase 1
• Whole Brain Radiation Therapy With Oxygen, With or Without RSR13, in Women With Brain Metastases From Breast CancerCompletedNCT00083304Phase 3